Arvinas, Inc. (ARVN)
NASDAQ: ARVN · IEX Real-Time Price · USD
31.77
-0.13 (-0.41%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Arvinas Employees
Arvinas had 445 employees on December 31, 2023. The number of employees increased by 30 or 7.23% compared to the previous year.
Employees
445
Change (1Y)
30
Growth (1Y)
7.23%
Revenue / Employee
$176,404
Profits / Employee
-$825,393
Market Cap
2.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 445 | 30 | 7.23% |
Dec 31, 2022 | 415 | 135 | 48.21% |
Dec 31, 2021 | 280 | 101 | 56.42% |
Dec 31, 2020 | 179 | 46 | 34.59% |
Dec 31, 2019 | 133 | 50 | 60.24% |
Dec 31, 2018 | 83 | 14 | 20.29% |
Dec 31, 2017 | 69 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
AMN Healthcare Services | 18,223 |
Guardant Health | 1,779 |
Inari Medical | 1,300 |
Ginkgo Bioworks Holdings | 1,218 |
agilon health | 1,117 |
Privia Health Group | 1,102 |
Intellia Therapeutics | 526 |
Denali Therapeutics | 445 |
ARVN News
- 6 days ago - Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer - GlobeNewsWire
- 19 days ago - Arvinas inks over $1.0 billion deal with Novartis - Invezz
- 20 days ago - Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer - GlobeNewsWire
- 6 weeks ago - Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arvinas Announces Chief Financial Officer Transition - GlobeNewsWire
- 2 months ago - Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease - GlobeNewsWire